Efficacy of cetuximab-based regimens after immune checkpoint inhibitor failure in recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and meta-analysis.
Oral OncolJun 6, 2026 (epub)
Clinical ResearchOncology (Medical)
Tomer Boldes, Uriel Oanunu, Omri Machnes et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy of cetuximab-based regimens in 411 patients with recurrent or metastatic head and neck squamous cell carcinoma after immune checkpoint inhibitor failure. The pooled objective response rate was 47%, with a median overall survival of 10.71 months, indicating clinically meaningful activity of cetuximab in this setting.
Key findings
- Pooled objective response rate was 47% (95% CI, 37%-56%) among evaluable patients.
- Pooled disease control rate was 70% (95% CI, 58%-80%) from 271 patients.
- Median progression-free survival was 4.69 months (95% CI, 3.30-6.67).
- Median overall survival was 10.71 months (95% CI, 5.15-22.29).
Why it matters
The findings provide important insights into treatment options for patients with recurrent or metastatic head and neck squamous cell carcinoma who have failed immune checkpoint inhibitors, highlighting the potential role of cetuximab-based therapies.